A Phase 3 interventional study of Larazotide Acetate and Placebo in Celiac Disease and Celiac Disease in Adolescents, sponsored by Interlude Biopharma Co.. Not yet recruiting. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Interlude Biopharma Co. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.
Larazotide acetate is being studied as a preventative therapy in individuals with well-controlled celiac disease. The primary objective of the study is to evaluate the protective effects of larazotide acetate compared to placebo on histologic changes and patient-reported outcomes following simulated inadvertent gluten exposure.
A total of 414 patients will be randomized 1:1:1 to receive either 0.25 mg larazotide acetate, 0.5 mg larazotide acetate, or placebo. All three study arms will take the assigned treatment as an oral capsule three times daily (TID). The treatment period will be 14 weeks, with an up to 8-week screening period and a 4-week follow-up period. During parts of the study, participants will also eat daily food bars that may contain a small amount of gluten, to simulate inadvertent gluten exposure in the real world. The doses of larazotide acetate being evaluated in this study were selected as the most promising doses to maximize efficacy based on previous clinical data.
Efficacy will be assessed via patient-reported outcomes, including but not limited to a daily and two weekly patient questionnaires, and histological changes, as evaluated via endoscopies with duodenal biopsy at screening/baseline and at the end of the treatment period. Safety will be assessed via adverse event reporting, laboratory evaluations, vital sign evaluations, and physical examinations at regular intervals.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
This study's planned enrollment of 414 is above the median of 50 across 215 interventional studies indexed under Celiac Disease.
Browse Celiac Disease studies →This is the only study on the registry with Interlude Biopharma Co. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has and is unwilling to use an acceptable method of for the duration of the study. Acceptable methods of birth control include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration of 0.25 mg larazotide acetate capsules, TID, for 14 weeks.
Drug: Larazotide Acetate
Oral administration of 0.5 mg larazotide acetate capsules, TID, for 14 weeks.
Drug: Larazotide Acetate
Oral administration of placebo capsules, TID, for 14 weeks.
Drug: Placebo
Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.
Placebo capsules will be taken orally TID for 14 weeks.
Proportion of responders treatment with larazotide acetate (0.25 mg or 0.5 mg) compared to placebo during the last two weeks of the 14-week treatment period
Responders are defined as participants who continue to meet the baseline criteria for well-controlled CeD, based on both symptom and histologic parameters, as outlined below: * Participant has a Weekly Celiac Disease Symptom Diary (CDSD) GI symptom severity score ≤ 0.400, with no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), and no individual GI symptom scores of severe or greater severity (a score of ≥3), for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score during the last two weeks of the 14-week treatment period (Weeks 13 to 14) * Participant has a Villous Height to Crypt Depth (Vh:Cd) ratio ≥2.5 at the end of the 14-week treatment period
Time frame: Last two weeks of the treatment period (Weeks 13-14)
Proportion of participants with a Vh:Cd ratio ≥2.5 at the end of the 14-week treatment period.
Vh:Cd ratio will be determined based on the Week 14 endoscopy with duodenal biopsy. Higher Vh:Cd ratios indicate a lesser extent of damage.
Time frame: End of treatment (Week 14)
Proportion of participants with a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent moderate score and no severe score, for core GI symptoms, during the last two weeks of the 14-week treatment period
The Weekly CDSD GI symptom severity score is an average of the daily GI symptom severity scores during the past 7 days. Higher scores indicate worse symptom severity. No persistent moderate score = no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days) No severe score = no individual GI symptom scores of severe or greater severity (a score of ≥3) Core GI symptoms of CeD = abdominal pain, bloating, diarrhea, and nausea, as measured by the CDSD v2.1 symptom severity score during the last two weeks of the 14-week treatment period.
Time frame: Last two weeks of the treatment period (Weeks 13-14)
Mean change from baseline in Vh:Cd ratio at the end of the 14-week treatment period
Vh:Cd ratios will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher Vh:Cd ratio indicates a lesser extent of damage.
Time frame: Baseline and End of treatment (Week 14)
Change from baseline in intraepithelial lymphocyte (IEL) density at the end of the 14-week treatment period
IEL density will be determined based on the endoscopy with duodenal biopsy from screening/baseline and Week 14. A higher IEL density indicates increased disease activity.
Time frame: Baseline and End of treatment (Week 14)
Proportion of weeks maintaining well-controlled disease-related symptoms during the 14-week treatment period
Well-controlled disease-related symptoms is defined as a Weekly CDSD GI symptom severity score ≤ 0.400, with no persistent individual symptom score of moderate severity (i.e., individual score of 2 on three or more consecutive days), and no individual GI symptom scores of severe or greater severity (a score of ≥3), for core GI symptoms of CeD (i.e., abdominal pain, bloating, diarrhea, and nausea), as measured by the CDSD v2.1 symptom severity score.
Time frame: Entire treatment period (14 weeks)
Proportion of symptom-free days, defined as no core GI symptoms of CeD for a 24-hour period
A symptom-free day is when all four core GI symptom scores (abdominal pain, bloating, diarrhea, nausea) are 0 during a 24-hour period, as measured by the CDSD v2.1 symptom severity score.
Time frame: Entire treatment period (14 weeks)
Incidence and severity of treatment-emergent adverse events
Time frame: First treatment through end of follow-up (~Week 18)
Incidence of treatment-related adverse events
Time frame: First treatment through end of follow-up (~Week 18)
Incidence of serious adverse events
Time frame: First treatment through end of follow-up (~Week 18)
Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation of study medication
Time frame: First treatment through end of treatment (Week 14)
Change from baseline in systolic blood pressure
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in diastolic blood pressure
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in heart rate
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in respiratory rate
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in oral temperature
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in weight
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
Change from baseline in Body Mass Index
Time frame: Baseline, Week 2, Week 6, Week 10, End of Treatment (Week 14), Follow-up (~Week 18)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Aug 2028, 18 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Larazotide acetate